Cargando…

Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine

As one of the best known cancer testis antigens, PRAME is overexpressed exclusively in germ line tissues such as the testis as well as in a variety of solid and hematological malignant cells including acute myeloid leukemia. Therefore, PRAME has been recognized as a promising target for both active...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Yushi, Zhou, Jihao, Wang, Lixin, Gao, Xiaoning, Ning, Qiaoyang, Jiang, Mengmeng, Wang, Jia, Wang, Lili, Yu, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734248/ https://www.ncbi.nlm.nih.gov/pubmed/23940586 http://dx.doi.org/10.1371/journal.pone.0070522

Ejemplares similares

Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
por: Zhang, Ningning, et al.
Publicado: (2019)

Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
por: Zhang, Na, et al.
Publicado: (2020)

Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia
por: Kong, Yi-Lin, et al.
Publicado: (2020)

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy
por: He, Yanjuan, et al.
Publicado: (2021)

The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF-κB pathway in multiple myeloma cells
por: Liu, Zhaoyun, et al.
Publicado: (2019)

Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study
por: Wang, Lixin, et al.
Publicado: (2020)

Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas
por: Tang, Zijiao, et al.
Publicado: (2023)

Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer
por: Zhang, Qingyuan, et al.
Publicado: (2018)

A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL
por: Wei, Chong, et al.
Publicado: (2021)

Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner
por: Yuan, Xiang-Gui, et al.
Publicado: (2019)

Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4
por: Jiang, Tao, et al.
Publicado: (2017)

Revisiting Estimates of CTL Killing Rates In Vivo
por: Yates, Andrew, et al.
Publicado: (2007)

Correction: Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4
por: Jiang, Tao, et al.
Publicado: (2018)

Rates of CTL Killing in Persistent Viral Infection In Vivo
por: Elemans, Marjet, et al.
Publicado: (2014)

Decitabine-based chemotherapy followed by haploidentical lymphocyte infusion improves the effectiveness in elderly patients with acute myeloid leukemia
por: Jing, Yu, et al.
Publicado: (2016)

Overcoming Resistance of Human Non-Hodgkin’s Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors
por: Torres-Collado, Antoni Xavier, et al.
Publicado: (2018)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer
por: Hu, Xingsheng, et al.
Publicado: (2016)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma
por: Wen, Tingyu, et al.
Publicado: (2022)

Successful treatment of early onset Epstein-Barr virus-negative T-cell lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation with histone deacetylase inhibitor chidamide
por: Fu, Hua-Rui, et al.
Publicado: (2021)

Investigating CTL Mediated Killing with a 3D Cellular Automaton
por: Graw, Frederik, et al.
Publicado: (2009)

Spatial Heterogeneity and Peptide Availability Determine CTL Killing Efficiency In Vivo
por: Hogan, Thea, et al.
Publicado: (2014)

Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing
por: Riccadonna, Cristina, et al.
Publicado: (2016)

Histone deacetylase inhibitor AR-42 and achiral analogues kill malaria parasites in vitro and in mice
por: Chua, Ming Jang, et al.
Publicado: (2021)

HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME)
por: Grillini, Marco, et al.
Publicado: (2022)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

The Expansion of the PRAME Gene Family in Eutheria
por: Chang, Ti-Cheng, et al.
Publicado: (2011)

Histone deacetylase inhibitors blocked activation and caused senescence of corneal stromal cells
por: Zhou, Qingjun, et al.
Publicado: (2008)

Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells
por: Hamed, Hossein A, et al.
Publicado: (2013)

Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition
por: Jennings, Victoria A., et al.
Publicado: (2019)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Targeting the Microtubule-Network Rescues CTL Killing Efficiency in Dense 3D Matrices
por: Zhao, Renping, et al.
Publicado: (2021)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

PRAME expression and clinical outcome of breast cancer
por: Epping, M T, et al.
Publicado: (2008)

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas
por: Bui, Chau M., et al.
Publicado: (2021)

PRAME expression is similar in scar and desmoplastic melanoma
por: Plotzke, Jaclyn M., et al.
Publicado: (2022)

PRAME induces genomic instability in uveal melanoma
por: Kurtenbach, Stefan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2qg4bvopnbap3s3ni0gsb5bsqa